![conference banner](/images/conference-banner.jpeg)
Abstract
Background: Recent investigations have implicated that Chitosan-nucleotide nanoparticles might be useful non-viral carriers in gene therapy. Polo-like kinase 1 (PLK1) has been reported to be an important oncogene that exerted considerable therapeutic merit in hepatocellular carcinoma (HCC).
Objective: We explored whether Galactosylated chitosan-graft-poly(ethylene glycol) (GCP) nanoparticlemediated delivery of PLK1 siRNA nucleotides could serve as an effective anti-cancer agent for HCC therapy. Method: GCP nanoparticles were prepared to deliver PLK1 siRNA oligos into HCC cells and tissues. Real-time fluorescence quantitative PCR (RFQ-PCR) and western blotting analyses were used to examine the efficiency of nanoparticle-mediated depletion of PLK1 in HepG2 cells. Cell proliferation and apoptotic death were also examined using flow cytometric, MTT and TUNEL assays. Xenograft mouse model was conducted to assess the impact of GCP/siRNA nanoparticles on the in vivo growth of HCC cells. Results: GCP nanoparticles bind to PLK1 siRNA efficiently. The particle size and zeta potential of GCP/siRNA nanoparticles are suitable for cellular delivery. PLK1-targeting nanoparticles inhibited cell proliferation through inducing G2/M phase arrest with a higher efficacy than a selective and potent PLK1 inhibitor BI 2536. Moreover, TUNEL assay revealed that PLK1-siRNA nanoparticles induced apparent apoptosis in HepG2 cells. In addition, PLK1-targeting nanoparticles induced significant upregulation of cellular p53, Bax and p21, whereas the level of Bcl-2 was impaired in HCC cells. Moreover, PLK1-targeting nanoparticles impaired the tumorigenicity of HepG2 cells in vivo. Conclusion: These findings indicate that PLK1-targeting nanoparticles exert considerable therapeutic merit and GCP/siRNA nanoparticles would be a valuable therapeutic carrier for HCC.Keywords: GCP nanoparticle, target therapy, PLK1, hepatocellular carcinoma, SiRNA, HCC cells.
Anti-Cancer Agents in Medicinal Chemistry
Title:Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma
Volume: 17 Issue: 7
Author(s): Dongzhi Wang, Renan Chang, Gang Wang, Baoying Hu, Yong Qiang and Zhong Chen*
Affiliation:
- Department of Hepatobiliary Surgery, Affiliated Hospital of Nantong University and Research Institute of Hepatobiliary Surgery of Nantong University, No. 20, Xisi Road, Nantong 226001, Jiangsu Province,China
Keywords: GCP nanoparticle, target therapy, PLK1, hepatocellular carcinoma, SiRNA, HCC cells.
Abstract: Background: Recent investigations have implicated that Chitosan-nucleotide nanoparticles might be useful non-viral carriers in gene therapy. Polo-like kinase 1 (PLK1) has been reported to be an important oncogene that exerted considerable therapeutic merit in hepatocellular carcinoma (HCC).
Objective: We explored whether Galactosylated chitosan-graft-poly(ethylene glycol) (GCP) nanoparticlemediated delivery of PLK1 siRNA nucleotides could serve as an effective anti-cancer agent for HCC therapy. Method: GCP nanoparticles were prepared to deliver PLK1 siRNA oligos into HCC cells and tissues. Real-time fluorescence quantitative PCR (RFQ-PCR) and western blotting analyses were used to examine the efficiency of nanoparticle-mediated depletion of PLK1 in HepG2 cells. Cell proliferation and apoptotic death were also examined using flow cytometric, MTT and TUNEL assays. Xenograft mouse model was conducted to assess the impact of GCP/siRNA nanoparticles on the in vivo growth of HCC cells. Results: GCP nanoparticles bind to PLK1 siRNA efficiently. The particle size and zeta potential of GCP/siRNA nanoparticles are suitable for cellular delivery. PLK1-targeting nanoparticles inhibited cell proliferation through inducing G2/M phase arrest with a higher efficacy than a selective and potent PLK1 inhibitor BI 2536. Moreover, TUNEL assay revealed that PLK1-siRNA nanoparticles induced apparent apoptosis in HepG2 cells. In addition, PLK1-targeting nanoparticles induced significant upregulation of cellular p53, Bax and p21, whereas the level of Bcl-2 was impaired in HCC cells. Moreover, PLK1-targeting nanoparticles impaired the tumorigenicity of HepG2 cells in vivo. Conclusion: These findings indicate that PLK1-targeting nanoparticles exert considerable therapeutic merit and GCP/siRNA nanoparticles would be a valuable therapeutic carrier for HCC.Export Options
About this article
Cite this article as:
Wang Dongzhi, Chang Renan, Wang Gang, Hu Baoying, Qiang Yong and Chen Zhong*, Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (7) . https://dx.doi.org/10.2174/1871520616666160926111911
DOI https://dx.doi.org/10.2174/1871520616666160926111911 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Advances in Nanomedicines and Targeted Therapies for Colorectal Cancer
Colorectal cancer remains a significant global health challenge, with high incidence and mortality rates despite advancements in treatment strategies. Conventional therapies often face limitations such as systemic toxicity, drug resistance, and suboptimal targeting. The advent of nanomedicines and innovative drug delivery systems offers new hope for overcoming these challenges and ...read more
Discovery of Lead compounds targeting transcriptional regulation
Transcriptional regulation plays key physiological functions in body growth and development. Transcriptional dysregulation is one of the important biomarkers of tumor genesis and progression, which is involved in regulating tumor cell processes such as cell proliferation, differentiation, and apoptosis. Additionally, it plays a pivotal role in angiogenesis and promotes tumor ...read more
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes that aid in stabilizing chromosomal makeup. The resynthesis of telomeres is supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no telomerase activity in human somatic cells, but the stem cells and germ cells undergo ...read more
Innovative targets in medicinal chemistry
Medicinal chemistry continuously evolves in response to emerging healthcare needs and advancements in scientific understanding. This special issue explores the current landscape of innovative targets in medicinal chemistry, highlighting the quest for novel therapeutic avenues. From traditional drug targets such as enzymes and receptors to emerging targets like protein-protein interactions ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Use of Transient Expression Systems for the Rapid Production of Virus-like Particles in Plants
Current Pharmaceutical Design The Influence of Macrophages and the Tumor Microenvironment on Natural Killer Cells
Current Molecular Medicine The Efficacy of Natural Bioactive Compounds for the Treatment of Nasopharyngeal Carcinoma
Mini-Reviews in Medicinal Chemistry Oncogene Expression Modulation in Cancer Cell Lines by DNA G-Quadruplex-Interactive Small Molecules
Current Medicinal Chemistry Small Interfering RNA for Effective Cancer Therapies
Mini-Reviews in Medicinal Chemistry Oxidative Stress and Cancer: The Role of Nrf2
Current Cancer Drug Targets Antiviral Drugs that Target Cellular Proteins May Play Major Roles in Combating HIV Resistance
Current Pharmaceutical Design Clinico-Pathologic and Biologic Predictors of EGFR Inhibitors Activity and Efficacy in Lung and in Colorectal Cancer
Current Signal Transduction Therapy Targeting the Ubiquitin-Proteasome Pathway in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Thiazole, Isatin and Phthalimide Derivatives Tested <i>in vivo</i> against Cancer Models: A Literature Review of the Last Six Years
Current Medicinal Chemistry Inhibitors of the Ubiquitin-Proteasome System and the Cell Death Machinery: How Many Pathways are Activated?
Current Molecular Pharmacology A Review on Chitosan in Drug Delivery for Treatment of Neurological and Psychiatric Disorders
Current Pharmaceutical Biotechnology Clinical Features of Scleroderma-Like Disorders: A Challenge for the Rheumatologist
Current Rheumatology Reviews Ceramide and Apoptosis: Exploring the Enigmatic Connections between Sphingolipid Metabolism and Programmed Cell Death
Anti-Cancer Agents in Medicinal Chemistry Targeting Never-In-Mitosis-A Related Kinase 5 in Cancer: A Review
Current Medicinal Chemistry Searching for New Targets and Treatments in the Battle Against Squamous Cell Carcinoma of the Head and Neck, with Specific Focus on Tumours of the Tongue
Current Topics in Medicinal Chemistry Integrin αvβ3 Antagonists for Anti-Angiogenic Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Investigation of Human Papilloma Virus Associated with Oral Cancer with an Insight into Diagnostic Approaches and Recent Patents
Recent Patents on Biomarkers Monoclonal Antibodies Carried in Drug Delivery Nanosystems as a Strategy for Cancer Treatment
Current Medicinal Chemistry ras Genes and Human Cancer: Different Implications and Different Roles
Current Genomics